Note 3 - Glaxosmithkline Agreement (Detail) (USD $)	3 Months Ended		6 Months Ended					117 Months Ended	6 Months Ended	117 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2010 Phase 2 Development [Member] Glaxosmithkline [Member] License Agreement Terms [Member]	May 31, 2011 Phase 2 Patient Enrollment [Member] Glaxosmithkline [Member] License Agreement Terms [Member]	Aug. 03, 2011 Development Services and Clinical Supply Agreement [Member] Glaxosmithkline [Member] License Agreement Terms [Member]	Dec. 31, 2011 Glaxosmithkline [Member] Maximum [Member] License Agreement Terms [Member]	Jun. 30, 2011 Glaxosmithkline [Member] License Agreement Terms [Member]	Dec. 31, 2011 Glaxosmithkline [Member] License Agreement Terms [Member]	Dec. 31, 2010 Glaxosmithkline [Member] License Agreement Terms [Member]
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned								$ 150,000,000		$ 16,000,000
Number of Payments Received										2
Payments Received On Licensing Arrangements					4,000,000	4,000,000	2,000,000			7,500,000	4,000,000
Licenses Revenue	$ 262,689	$ 705,162	$ 525,378	$ 1,267,851					$ 642,000